方法：通过频域光相干断层扫描仪检测患者的黄斑部视网膜的厚度，以黄斑为中心进行容积扫描，生成1、3、6mm三个环九个区域的平均厚度数据，并进行统计学分析。

结果：研究纳入健康对照组、口服降血糖药物组、胰岛素治疗组三组患者，各组均为22例22眼。健康对照组黄斑区各环视网膜厚度分别为：第1环268.09±17.97μm，第2环340.41±22.25μm，第3环298.14±12.90μm。口服降血糖药物治疗组黄斑区各环视网膜厚度分别为：第1环260.00±18.17μm，第2环335.44±21.12μm，第3环295.63±15.92μm。胰岛素治疗组黄斑区各环视网膜厚度分别为：第1环271.01±26.09μm，第2环340.86±17.10μm，第3环298.57±12.14μm。三组黄斑区第1环视网膜厚度的差异无统计学意义(F=1.21，P=0.31)，第2环的差异无统计学意义(F=0.35，P=0.71)，第3环的差异亦无统计学意义(F=0.22，P=0.81)。

结论：与健康者相比，口服降糖药物和胰岛素治疗均未改变无眼底并发症的糖尿病患者的黄斑区视网膜厚度。

METHODS: The macular thickness was measured by optical coherence tomography(OCT). The retina volume on the center of macula was scanned, and it generated automatically the average thickness data of three rings and nine areas of 1mm, 3mm and 6mm. The data were statistically analyzed.

RESULTS: Healthy control group, oral hypoglycemic drug group and insulin treatment group were enrolled. Each group included 22 cases 22 eyes. The macular retinal thickness of healthy control group is 268.09±17.97μm(the 1^st ring), 340.41±22.25μm(the 2^nd ring)and 298.14±12.90μm(the 3^rd ring), respectively. The macular thickness of oral hypoglycemic drug group is 260.00±18.17μm(the 1^st ring), 335.44±21.12μm(the 2^nd ring)and 295.63±15.92μm(the 3^rd ring), respectively. The macular thickness of insulin therapy group is 271.01±26.09μm(the 1^st ring), 340.86±17.10μm(the 2^nd ring)and 298.57±12.14μm(the 3^rd ring), respectively. Comparison of the macular thickness of the 1^st ring among 3 groups was insignificant(F=1.21, P=0.31), neither the comparison of the 2^nd ring(F=0.35, P=0.71), neither the comparison of the 3^rd ring(F=0.22, P=0.81).

CONCLUSION: Compared with healthy individuals, both oral antidiabetic medicines and insulin therapy don't alter the macular thickness of patients with diabetes while without fundus complication.